Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30693313 | 1.00 | ROCK2 (1.00) | ROCK2PDE10A | |
| SCHEMBL29708450 | 1.00 | ROCK2 (1.00) | ROCK2PDE10A | |
| SCHEMBL29708565 | 0.89 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL23379672 | 0.89 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL20653161 | 0.88 | ROCK2 (0.84) | ROCK2 | |
| SCHEMBL20641293 | 0.88 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL23356659 | 0.88 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL30693314 | 0.88 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL29708241 | 0.88 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL25269641 | 0.88 | ROCK2 (0.85) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110869360-B | Phenylacetamides as ROCK inhibitors | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | claimed |
| EP-3652164-B1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2023-06-21 | — | — | EP | claimed |
| EP-3652164-B1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-3652164-B1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2023-06-21 | — | — | EP | disclosed |
| US-11306081-B2 | Phenylacetamides as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-19 | — | — | US | disclosed |
| US-11306081-B2 | Phenylacetamides as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210147407-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147407-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147407-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | MYLK, ROCK1, ROCK2 | ROCK2 3/4885PDE10A 216/4885 |
| US-11306081-B2 | Phenylacetamides as inhibitors of rock | MYLK, ROCK1, ROCK2 | ROCK2 3/4885PDE10A 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.